Delic Survey Shows Americans With Mental Health Conditions Are Ready For Access To Psychedelics
The results of an online survey conducted last month by Delic Holdings Corp. (CNSX: DELC) (OTCMKTS: DELCF) aren’t surprising: Americans experiencing mental health conditions like depression and anxiety are becoming increasingly aware of psychedelics as a potential treatment—and they want access to them.
Out of 953 adults polled who suffer from anxiety, depression, or post-traumatic stress disorder and have used prescription medication as treatment, 65 percent said they believed that psychedelic medicines like MDMA, ketamine, and psilocybin should be made available to patients living with treatment-resistant conditions.
Based on the self-reported survey data, 63 percent said that while their prescription medications like SSRIs were helpful, they still experienced anxiety, depression, or symptoms of post-traumatic stress. Another 18 percent of participants said their medication either failed to improve their condition or made it worse.
Additionally, 83 percent of those experiencing anxiety, depression, or PTSD said they would be open to trying “alternative treatments proven to be more effective than prescription medication with fewer side effects,” with 66 percent of respondents saying they would be open to ketamine if it fit the criteria.
Sixty-two percent of respondents said the same about psilocybin if it were to be prescribed by a physician, while 56 percent said they would be open to MDMA treatment, with the same stipulation—that it came with a doctor’s recommendation.
The survey was conducted by The Harris Poll on behalf of Delic, and while it is not based on a probability sample, it does show that many people who are receiving first-line treatments for depression, anxiety, and PTSD aren’t getting better.
“We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and laywmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” said CEO and co-founder Matt Stang in a press release, noting that the economic cost of untreated mental illness in the United States exceeds $300 billion in lost productivity.
Delic Corp. operates several businesses in the psychedelic space including a large network of clinics, Ketamine Infusion Centers and Ketamine Wellness Centers, as well as Delic Labs, the only entity licensed by Health Canada to research psilocybin vaporization technology.